627 The effect of LNS8801 in combination with pembrolizumab in patients with treatment-refractory cutaneous melanoma

• Sapna Patel,
• Alain Mita,
• Kyriakos P Papadopoulos,
• Justine Cohen,
• Alexander Shoushtari,
• Jordi Rodon,
• Marlana Orloff,
• Marya Chaney,
• Carolyn Muller,
• Jessica Lin,
• Tina Garyantes,
• Monica Mita,
• Christopher Natale,
• Jeffrey Ishizuka

Affiliations

Sapna Patel

1MD Anderson Cancer Center, Houston, TX, USA

Alain Mita

Cedars-Sinai Medical Center, Los Angeles, California, USA

Kyriakos P Papadopoulos

10START San Antonio, San Antonio, TX, USA

Justine Cohen

Division of Oncology, Department of Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, USA

Alexander Shoushtari

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA

Jordi Rodon

Department of Investigational Cancer Therapeutics (Phase 1 Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Marlana Orloff

14Thomas Jefferson University Hospital, Philadelphia, PA, USA

Marya Chaney

7Merck and Co, Inc., Kenilworth, NJ, USA

Carolyn Muller

8University of New Mexico, Albuquerque, NM, USA

Jessica Lin

Division of Adolescent/Young Adult Medicine, Boston Children`s Hospital, Boston, Massachusetts, USA

Tina Garyantes

4Linnaeus Therapeutics, Haddonfield, NJ, USA

Monica Mita

7Cedars Sinai Medical Center, Los Angeles, CA, USA

Christopher Natale

4Linnaeus Therapeutics, Haddonfield, NJ, USA

Jeffrey Ishizuka

6Yale University, Woodbridge, CT